Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1960 1
1968 1
1971 1
1973 1
1975 1
1980 1
1982 4
1983 2
1985 3
1986 2
1987 3
1988 5
1989 6
1990 1
1991 2
1992 4
1993 3
1994 2
1995 3
1996 6
1997 3
1998 4
1999 7
2000 2
2001 2
2002 3
2003 3
2004 4
2005 5
2006 7
2007 13
2008 8
2009 9
2010 11
2011 12
2012 15
2013 9
2014 17
2015 14
2016 15
2017 17
2018 21
2019 20
2020 11
Text availability
Article attribute
Article type
Publication date

Search Results

263 results
Results by year
Filters applied: . Clear all
Page 1
Erythrodermic psoriasis: pathophysiology and current treatment perspectives.
Singh RK, Lee KM, Ucmak D, Brodsky M, Atanelov Z, Farahnik B, Abrouk M, Nakamura M, Zhu TH, Liao W. Singh RK, et al. Version 2. Psoriasis (Auckl). 2016;6:93-104. doi: 10.2147/PTT.S101232. Epub 2016 Jul 20. Psoriasis (Auckl). 2016. PMID: 28856115 Free PMC article.
Erythrodermic psoriasis (EP) is a rare and severe variant of psoriasis vulgaris, with an estimated prevalence of 1%-2.25% among psoriatic patients. ...In 2010, the medical board of the US National Psoriasis Foundation published consensus guidelines adv
Erythrodermic psoriasis (EP) is a rare and severe variant of psoriasis vulgaris, with an estimated prevalence of 1%-2.2
Psoriasis: from Pathogenesis to Targeted Therapies.
Conrad C, Gilliet M. Conrad C, et al. Clin Rev Allergy Immunol. 2018 Feb;54(1):102-113. doi: 10.1007/s12016-018-8668-1. Clin Rev Allergy Immunol. 2018. PMID: 29349534 Review.
Over the last decade, the management of psoriasis has witnessed a paradigm shift. Thanks to the increasing knowledge about the pathogenesis of psoriasis, targeted treatments with monoclonal antibodies have been developed. ...Recently, molecular and genetic studies i …
Over the last decade, the management of psoriasis has witnessed a paradigm shift. Thanks to the increasing knowledge about the pathog …
Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
Saeki H, Nakagawa H, Nakajo K, Ishii T, Morisaki Y, Aoki T, Cameron GS, Osuntokun OO; Japanese Ixekizumab Study Group. Saeki H, et al. J Dermatol. 2017 Apr;44(4):355-362. doi: 10.1111/1346-8138.13622. Epub 2016 Oct 11. J Dermatol. 2017. PMID: 27726163 Free PMC article. Clinical Trial.
Most patients with erythrodermic psoriasis or generalized pustular psoriasis responded to ixekizumab and the clinical outcome was maintained over 52 weeks (75% and 60% of patients achieved sPGA [0, 1] at week 52, respectively). ...In conclusion, 52-week ixeki …
Most patients with erythrodermic psoriasis or generalized pustular psoriasis responded to ixekizumab and the clinical o …
Erythrodermic Psoriasis and HIV Infection.
Bowles AA, Smirnov B. Bowles AA, et al. N Engl J Med. 2019 Jan 3;380(1):80. doi: 10.1056/NEJMicm1810005. N Engl J Med. 2019. PMID: 30601728 Free article. No abstract available.
A systematic review of treatment strategies for erythrodermic psoriasis.
Reynolds KA, Pithadia DJ, Lee EB, Liao W, Wu JJ. Reynolds KA, et al. J Dermatolog Treat. 2019 Nov 12:1-7. doi: 10.1080/09546634.2019.1689228. Online ahead of print. J Dermatolog Treat. 2019. PMID: 31682547
Background: Erythrodermic psoriasis (EP) is a severe, rare form of psoriasis that can be life threatening. Treatment of EP is usually based on anecdotal evidence or past clinical experience, which is in part due to the rarity and often emergent nature of this …
Background: Erythrodermic psoriasis (EP) is a severe, rare form of psoriasis that can be life threatening. Treatment of …
Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study.
Sano S, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Sano S, et al. J Dermatol. 2018 May;45(5):529-539. doi: 10.1111/1346-8138.14294. Epub 2018 Mar 22. J Dermatol. 2018. PMID: 29569397 Free PMC article. Clinical Trial.
Generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP) are the rare and severe subtypes of psoriasis, which are often difficult to treat. ...Furthermore, guselkumab treatment consistently showed improvement in responses of secondary end- …
Generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP) are the rare and severe subtypes of psoriasis
Erythrodermic psoriasis and secukinumab: Our clinical experience.
Mateu-Puchades A, Santos-Alarcón S, Martorell-Calatayud A, Pujol-Marco C, Sánchez-Carazo JL. Mateu-Puchades A, et al. Dermatol Ther. 2018 Jul;31(4):e12607. doi: 10.1111/dth.12607. Epub 2018 Apr 16. Dermatol Ther. 2018. PMID: 29663615 No abstract available.
Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J).
Okubo Y, Mabuchi T, Iwatsuki K, Elmaraghy H, Torisu-Itakura H, Morisaki Y, Nakajo K. Okubo Y, et al. J Eur Acad Dermatol Venereol. 2019 Feb;33(2):325-332. doi: 10.1111/jdv.15287. Epub 2018 Nov 15. J Eur Acad Dermatol Venereol. 2019. PMID: 30317671 Free PMC article. Clinical Trial.
BACKGROUND: Erythrodermic and generalized pustular psoriasis are rare, difficult to treat forms of psoriasis. In previous reports, we documented 24- and 52-week findings of an open-label, phase 3 trial (UNCOVER-J) of ixekizumab in Japanese patients with er
BACKGROUND: Erythrodermic and generalized pustular psoriasis are rare, difficult to treat forms of psoriasis. In previo …
Organizing Pneumonia Complicated with Erythrodermic Psoriasis.
Nakamura H, Nakayama D, Tanaka S, Horita T. Nakamura H, et al. Intern Med. 2019 Dec 15;58(24):3597-3598. doi: 10.2169/internalmedicine.3299-19. Epub 2019 Aug 21. Intern Med. 2019. PMID: 31434824 Free PMC article. No abstract available.
263 results
Jump to page
Feedback